Merck & Co Inc
6MK
Company Profile
Business description
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).
Contact
126 East Lincoln Avenue
RahwayNJ07065
USAT: +1 908 740-4000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
75,000
Stocks News & Analysis
stocks
SpaceX is scaling AI infrastructure on earth, data centers in space might be next
Our view on the first results as a publicly traded company.
stocks
A look into newly listed Glencore’s valuation
A new ASX heavyweight with coal, copper and trading exposure.
stocks
Meta is up 9% this year. Is it still a buy ahead of earnings?
We’ll be watching Muse agent adoption, revenue growth, and more.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,956.60 | 12.40 | 0.14% |
| CAC 40 | 7,921.68 | 83.19 | 1.06% |
| DAX 40 | 25,645.04 | 340.62 | 1.35% |
| Dow JONES (US) | 52,789.48 | 293.60 | 0.56% |
| FTSE 100 | 10,752.88 | 19.88 | 0.19% |
| HKSE | 23,651.87 | 215.87 | -0.90% |
| NASDAQ | 26,740.63 | 315.81 | 1.20% |
| Nikkei 225 | 64,621.24 | 545.82 | 0.85% |
| NZX 50 Index | 13,761.29 | 129.60 | 0.95% |
| S&P 500 | 7,764.56 | 51.99 | 0.67% |
| S&P/ASX 200 | 8,831.30 | 14.40 | 0.16% |
| SSE Composite Index | 3,713.03 | 22.34 | -0.60% |